Rehovot based biopharmaceutical company Kamada has announced that they have started to work on developing a blood-plasma derived treatment against the coronavirus.
“The concept that we are developing is not new: people that are exposed to a virus develop antibodies for that virus. If patients who have recovered from the disease and are in convalescence donate plasma, there is a very good likelihood that in that plasma there are going to be antibodies,” Amir London, Chief Executive Officer of Kamada, told The Jerusalem Post.
Comments are closed.